Hospital-Treated COVID-19 | Executive Insights | Multiple Geographies | 2020
The treatment landscape for COVID-19 is rapidly evolving, as such, intense research is focused on approaches designed to reduce viral load and/or improve outcomes in hospitalized patients infected with SARS-CoV-2. Currently, Veklury (remdesivir) is the only approved drug for hospitalized COVID-19 patients in the United States; the agent holds a conditional marketing authorization in Europe and can be used under an exceptional approval pathway in Japan. The disease poses a high burden to the healthcare system, and presents a high unmet need. A myriad of drugs with diverse mechanisms of action are in clinical development for hospitalized COVID-19 patients. Should any of these pipeline candidates launch into the COVID-19 marketplace, it will transform the treatment landscape and help address the existing unmet need.Paste Abstract text here
